D-Day For KPTI Today

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI) is slated to provide an overview of top-line results from its phase 2b study of oral Selinexor in multiple myeloma, dubbed STORM, today.

The STORM study is evaluating Selinexor in heavily-pretreated patients with *quad-refractory multiple myeloma. *If there has been a response of only 25% or less to Revlimid, Pomalyst, Velcade, and Kyprolis, or progression of the disease during therapy or within 60 days after completion of therapy, it is known as quad-refractory multiple myeloma.

The first cohort of the STORM study has enrolled 80 patients and data from this cohort are expected to be available today (September 6, 2016).

The company intends to expand the STORM study to include approximately 120 additional patients with penta-refractory multiple myeloma.

Will there be a blessing in the STORM for Karyopharm? Please stay tuned for new updates.